Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection.

Newcombe NG, Johansson ES, Au G, Lindberg AM, Barry RD, Shafren DR.

J Virol. 2004 Feb;78(3):1431-9.

2.

Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.

Johansson ES, Xing L, Cheng RH, Shafren DR.

J Virol. 2004 Nov;78(22):12603-12.

3.

Novel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivity.

Newcombe NG, Beagley LG, Christiansen D, Loveland BE, Johansson ES, Beagley KW, Barry RD, Shafren DR.

J Virol. 2004 Nov;78(22):12677-82.

4.

Cellular receptor interactions of C-cluster human group A coxsackieviruses.

Newcombe NG, Andersson P, Johansson ES, Au GG, Lindberg AM, Barry RD, Shafren DR.

J Gen Virol. 2003 Nov;84(Pt 11):3041-50.

PMID:
14573809
5.

Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry.

Shafren DR, Dorahy DJ, Ingham RA, Burns GF, Barry RD.

J Virol. 1997 Jun;71(6):4736-43.

6.

Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.

Skelding KA, Barry RD, Shafren DR.

Invest New Drugs. 2012 Apr;30(2):568-81. doi: 10.1007/s10637-010-9614-0. Epub 2010 Dec 21.

PMID:
21170760
7.

Binding to decay-accelerating factor is not required for infection of human leukocyte cell lines by enterovirus 70.

Haddad A, Nokhbeh MR, Alexander DA, Dawe SJ, Grisé C, Gulzar N, Dimock K.

J Virol. 2004 Mar;78(6):2674-81.

8.
9.

Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21.

Skelding KA, Barry RD, Shafren DR.

Breast Cancer Res Treat. 2009 Jan;113(1):21-30. doi: 10.1007/s10549-008-9899-2. Epub 2008 Feb 7.

PMID:
18256929
10.

The crystal structure of coxsackievirus A21 and its interaction with ICAM-1.

Xiao C, Bator-Kelly CM, Rieder E, Chipman PR, Craig A, Kuhn RJ, Wimmer E, Rossmann MG.

Structure. 2005 Jul;13(7):1019-33.

11.
12.

Two clusters of mutations map distinct receptor-binding sites of echovirus 11 for the decay-accelerating factor (CD55) and for canyon-binding receptors.

Rezaikin AV, Novoselov AV, Sergeev AG, Fadeyev FA, Lebedev SV.

Virus Res. 2009 Oct;145(1):74-9. doi: 10.1016/j.virusres.2009.06.004. Epub 2009 Jun 18.

PMID:
19540285
13.

Potent oncolytic activity of human enteroviruses against human prostate cancer.

Berry LJ, Au GG, Barry RD, Shafren DR.

Prostate. 2008 May 1;68(6):577-87. doi: 10.1002/pros.20741.

PMID:
18288643
14.

The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55).

Karnauchow TM, Tolson DL, Harrison BA, Altman E, Lublin DM, Dimock K.

J Virol. 1996 Aug;70(8):5143-52.

15.

Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.

Au GG, Lincz LF, Enno A, Shafren DR.

Br J Haematol. 2007 Apr;137(2):133-41.

PMID:
17391493
16.
18.

Cytolytic replication of coxsackievirus B2 in CAR-deficient rhabdomyosarcoma cells.

Polacek C, Ekström JO, Lundgren A, Lindberg AM.

Virus Res. 2005 Nov;113(2):107-15.

PMID:
15964091
19.

Study of Coxsackie B viruses interactions with Coxsackie Adenovirus receptor and Decay-Accelerating Factor using Human CaCo-2 cell line.

Riabi S, Harrath R, Gaaloul I, Bouslama L, Nasri D, Aouni M, Pillet S, Pozzetto B.

J Biomed Sci. 2014 May 21;21:50. doi: 10.1186/1423-0127-21-50.

20.

Antibody binding to individual short consensus repeats of decay-accelerating factor enhances enterovirus cell attachment and infectivity.

Shafren DR, Dorahy DJ, Thorne RF, Kinoshita T, Barry RD, Burns GF.

J Immunol. 1998 Mar 1;160(5):2318-23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk